Skip to content

Baduanjin Sequential Therapy and Cardiac Function of AMI With Reduced EF After PCI

Effect of Baduanjin Sequential Therapy on the Cardiac Function and Exercise Endurance in Patients With AMI and Reduced Ejection Fraction After Primary PCI

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05201274
Acronym
BST-AMI
Enrollment
140
Registered
2022-01-21
Start date
2021-11-11
Completion date
2023-02-11
Last updated
2022-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AMI

Keywords

Acute myocardial infarction, Baduanjin, Percutaneous coronary intervention, Cardiac function, Physical function

Brief summary

Acute myocardial infarction (AMI) is one of the leading causes of death around the world, with the potential for substantial morbidity and mortality. The increasing evidence indicates that exercise training has beneficial effects on LV remodelling in post-MI patients with greater benefits occurring when training earlier following MI, among which the earliest time for rehabilitation is one week after myocardial infarction. However, the effect of Baduanjin sequential therapy for patients after one week of AMI has yet to be assessed. Therefore, the aim of this study is to assess the impact of Baduanjin sequential therapy on cardiac and physical function in patients with AMI and reduced ejection fraction after primary PCI.

Interventions

A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003.

BEHAVIORALAerobic exercise

Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.

Sponsors

Shenyang Northern Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Acute myocardial infarction undergoing primary percutaneous coronary intervention; * Aged 18 years or over and under 80 years; * 35% \< LVEF \< 50% and LV \< 65mm; * With informed consents

Exclusion criteria

* Severe symptomatic congestive heart failure (KILLIP cardiac function class III-IV); * Malignant arrhythmias (ventricular fibrillation, ventricular tachycardia, frequent multiple source ventricular premature); * Uncontrolled hypertension (systolic blood pressure greater than 160mmhg, diastolic blood pressure greater than 100mmhg); * Life-threatening diseases with limited life expectancy \<6 months; * Inability or difficulty to exercise; * Participation in other clinical trials

Design outcomes

Primary

MeasureTime frameDescription
Left ventricular ejection fraction (LVEF)baseline and 3 monthsThe change in echocardiographic measures of left ventricular ejection fraction,(LVEF). LVEF in %.

Secondary

MeasureTime frameDescription
SF-36baseline and 3 monthsthe SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.
Generalized Anxiety Disorder 7-item (GAD-7)baseline and 3 monthsThe Generalized Anxiety Disorder 7 (GAD-7) is a 7-item instrument used to briefly measure or assess one of the most common mental disorders.
Patient Health Questionnaire (PHQ-9)baseline and 3 monthsThe PHQ-9 is the depression module, which scores each of the nine DSM-IV criteria as 0 (not at all) to 3 (nearly every day). It has been validated for use in primary care. It is not a screening tool for depression but it is used to monitor the severity of depression and response to treatment.
Seattle Angina Questionnaire (SAQ)baseline and 3 monthsThe Seattle Angina Questionnaire (SAQ), developed by Spertus and first reported in the literature in 1994, increasingly is being used to measure cardiac disease-specific quality of life in patients with CAD and
Minnesota Satisfaction Questionnaire (MSQ)baseline and 3 monthsThe Minnesota Satisfaction Questionnaire (MSQ) is initially designed to measure an employee's satisfaction with his or her job.
Traditional Chinese Medicine (TCM) symptom score scalebaseline and 3 monthsTraditional Chinese Medicine (TCM) symptom score scale is a score scale for evaluating patients' symptoms from the perspective of TCM. The full score is 30 points, 7-14 points are mild, 15-22 points are moderate and ≥23 points are severe.
CPET operators-Peak VO2/kgbaseline and 3 monthsCardiopulmonary exercise testing ( CPET) is one kind of integrative evaluation of the subject's cardiopulmonary function under a certain exercise load. The information gathered during a CPET is used to calculate Peak VO2 (the highest level of oxygen consumption attained at peak exercise). (ml/kg/min)
CPET operators-metabolic equivalent (METs)baseline and 3 monthsIn cardiology, and especially when treadmill protocols are used, it is common to express the metabolic requirement for external work as the metabolic equivalent (MET). MET is defined as the equivalent of the resting metabolic oxygen requirement. One metabolic equivalent equals 3.5 ml/kg per minute. Exercise capacity (in METS) is a powerful predictor of mortality among men referred for exercise testing. (unit in METs)
LV end-diastolic volume (LVEDV)baseline and 3 monthsThe change in echocardiographic measures of ventricular volumes (LV end-diastolic volume). LVEDV in ml.
LV end-systolic volume (LVESV)baseline and 3 monthsThe change in echocardiographic measures of ventricular volumes (LV end-systolic volume). LVESV in ml.
CPET operators-peak O2-pulsebaseline and 3 monthsAnother value calculated by CPET is the peak O2-pulse, which indicates how much blood one's heart can pump out with each beat (at the peak level of exercise). (ml/beat)
6-minute walk distance (6MWD)baseline and 3 monthsA 6-minute walk test measures the distance patients can quickly walk in 6 minutes. (in meters)
Exercise compliance-exercise timebaseline and 3 monthsExercise time. (in minutes)
Exercise compliance-Exercise frequencybaseline and 3 monthsExercise frequency. (per week)
N-terminal pro-brain natriuretic peptide (NT-pro BNP)baseline and 3 monthsN-terminal pro-brain natriuretic peptide (NT-pro BNP) in pg/ml

Other

MeasureTime frameDescription
The occurrence and composite of major adverse cardiac and cerebrovascular event (MACCE)baseline and 3 monthsdefined as recurrent myocardial infarction, any revascularization, readmission, stent thrombosis (ST) all-cause death and stroke)
Adverse events related to exercise rehabilitationbaseline and 3 monthsAdverse events related to exercise rehabilitation, such as fall.

Countries

China

Contacts

Primary ContactMeili Liu, MD
liumeili1983bl@163.com86-18940193302
Backup ContactYaling Han, MD
hanyaling@163.net86-24-23922184

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026